All Journal Entries Journals
Sort By:  

herpevac vaccine failure

Jan 14, 2012 - 0 comments
Tags:

herpes vaccine

,

herpevac



http://www.nejm.org/doi/full/10.1056/NEJMoa1103151


Unfortunately it only reduced the risk of hsv2 transmission by about 20% so it's not worth marketing.  

grace

What is BV?

Jan 11, 2012 - 1 comments

We talk about BV quite a bit on the herpes and std forums so I thought it would be best to post more info on it.

Bv is bacterial vaginosis. It's very common in women who are sexually active.  

Bv makes you more likely to contract a std in general as well as it can make genital herpes reoccur more often so asking to be tested for it when you are seen is always a good idea.  About half of all women who have bv, don't get obvious symptoms so if your provider tells you you have it but doesn't feel it's necessary to treat you because you aren't having bothersome symptoms, be sure to ask to be treated for it anyways to reduce your chances of contracting a std!

http://www.cdc.gov/std/bv/stdfact-bacterial-vaginosis.htm

also something to keep in mind - after using vaginal bv treatments, it's not unusual to get a thick, chunky type discharge for a few days. This is dead bacteria being expelled from your vagina and it will go away on its own in a few days.  Don't think it's a yeast infection and self treat for yeast, give it a few days and it should be gone. Cleansing the genital area with cool water is often helpful to keep from getting irritated from this chunky discharge.



grace

NY times talks about herpes

Aug 29, 2011 - 1 comments
Tags:

Genital Herpes

,

oral sex

,

Pregnancy



Dr Peter Leone, one of the top std practitioners in the US, recently did a series of articles/blogs for the NY times. Here are the links to them for information on herpes :)


http://consults.blogs.nytimes.com/2010/06/01/dating-sex-and-herpes/

http://consults.blogs.nytimes.com/2010/05/31/is-herpes-a-danger-during-pregnancy/

http://consults.blogs.nytimes.com/2010/05/28/can-oral-sex-spread-herpes/

http://consults.blogs.nytimes.com/2010/05/26/5-things-to-know-about-herpes/

Happy reading :)

grace

update on phase 2 aic316

Jul 23, 2011 - 1 comments

http://www.aicuris.com/index.php/fuseaction/download/lrn_file/20110718-press-release-aic316-phase-ii-en-final.pdf

AiCuris’ novel HSV compound AIC316 shows efficacy in phase II

Wuppertal, July 18, 2011 – Phase II results for AiCuris' novel non-nucleosidic herpes simplex virus (HSV) inhibitor AIC316 reveal safety and efficacy in persons with genital herpes. The data were presented at the 19th ISSTDR Meeting (International Society for Sexually Transmitted Diseases Research) in Quebec, Canada, by the coordinating investigator of the trial, Professor Anna Wald from the University of Washington and Fred Hutchinson Cancer Research Center in Seattle, USA,
156 HSV-2 positive participants (105 women and 51 men) were randomized between May 2010 and October 2010 at seven sites in the US. The goal of the trial was to compare the efficacy of four different doses of AIC316 (5, 25, and 75 mg once daily, or 400 mg once weekly) and placebo with respect to the suppression of HSV shedding. All participants received the study drug or placebo daily or weekly for 4 weeks.
AIC316 was safe and well tolerated at all doses administered and led to a significant reduction of viral shedding in a dose dependent manner. The strongest treatment effect was seen in the 400 mg once weekly and the 75 mg once daily dosing groups. Moreover, AIC316 led to a significant reduction of the amount of HSV found. This highly suppressive effect of AIC316 on viral replication also correlated with a significant clinical benefit: the proportion of days with reported genital lesions was reduced from 13,7 % to 1,1 %; the number of recurrences was substantially reduced as well.
”We are very pleased with these data as HSV therapy has not seen much innovation in more than a decade. Our data confirm an excellent antiviral efficacy in humans, a clear dose response and an overall good safety profile. The innovative trial design that used shedding was important to show clearly the benefit of our drug and identify doses for further development”, says Prof. Helga Rübsamen-Schaeff, CEO at AiCuris. “The significant clinical benefit of reduced lesions and recurrences combined with a good safety profile are very encouraging for the further development of our drug” adds Dr. Marie-Paule Richard, CMO at AiCuris.
***